| Literature DB >> 32420775 |
Chezi Ganzel1,2, Ron Ram3, Alexander Gural4, Ofir Wolach5, Sharon Gino-Moor6, Vladimir Vainstein4, Boaz Nachmias4, Arie Apel7, Maya Koren-Michowitz7, Oren Pasvolsky5, Ronit Yerushalmi8, Ivetta Danylesko8, Yosef Cohen9, Galit Peretz10, Yakir Moshe3, Miri Zektser10, Shay Yeganeh11, Jacob M Rowe1,12, Yishai Ofran1.
Abstract
Data from 11 Israeli centers, where venetoclax was used for relapsed/refractory AML after intensive chemotherapy, were retrospectively collected. During 2016-2019, forty patients were identified. Median age was 67 years (21-82), 60% males, median of 2(1-4) prior lines of treatment and 42% relapsed after allogeneic transplant. 62.5% of the patients received the venetoclax with hypomethylating agents and 22.5% with low dose cytarabine. Median follow-up was 5.5 months. Of the 29 patients who survived for more than two cycles of therapy, 22 (76%) achieved neutrophil recovery and 59% (n = 17) recovered also their platelet count. In 15 (52% of those who survived > 2 months), CR/CRi was confirmed by bone marrow examination. The median OS from venetoclax initiation of all the patients and of those who survived more than 2 months was 5.5 and 6.5 months, respectively. In conclusion, this study demonstrates that venetoclax is safe and active also in AML patients with advanced disease.Entities:
Keywords: Acute myeloid leukemia; refractory; relapse; venetoclax
Mesh：
Substances：
Year: 2020 PMID： 32420775 DOI： 10.1080/10428194.2020.1761964
Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022